Triglyceride plus HDL-C level identifies subpopulations at increased risk of CHD or stroke
27-3-2017 • Lee JS, et al, Diabetes Care 2017
High fasting triglyceride levels plus low HDL-C levels were associated with increased risks of incident CHD and ischaemic stroke, particularly in diabetic patients and those with LDL-C ≥130 mg/dL.
News • 22-3-2017
Efficacy of usual care for hypertension enhanced with use of e-counselling tool
The REACH trial demonstrated that after 12 months of use of an e-counselling programme, hypertensives showed 10 mmHg lower SBP and improvement of other risk factors.
News • 22-3-2017
PCSK9 inhibitor does not affect cognitive functioning in CVD patients, not even at very low LDL-c
No difference in cognitive function was seen between evolocumab and placebo-treated patients in the EBBINGHAUS trial. No cognitive decline was seen over time in either treatment group.
News • 20-3-2017
CV benefit of consistent LDL-c lowering with PCSK9 antibody in high-risk patients on statins
The FOURIER trial showed stable LDL-c reduction with evolocumab by about 60% during 3 years in statin-treated CVD patients, and lower CV event rates. event curves continued to diverge over time.
More arterial stiffness in heavy alcohol consumers
2-3-2017 • O’Neill D, et al, JAHA, 2017
Using alcohol consumption data of 25 years, it was found that especially male heavy drinkers have increased arterial stiffness, and over time, pulse wave velocity of non-drinkers increased most.
E-cigarette use may not be harmless
1-3-2017 • Moheimani RS, et al, JAMA Cardiol, 2017
Habitual e-cigarette use was associated with a shift in cardiac autonomic balance toward sympathetic predominance and increased oxidative stress, both associated with increased CV risk.
News • 23-3-2017
Statin did not convincingly affect verbal or nonverbal memory function
First study investigating the effects of statins on the CNS using fMRI, showed few differences between atorvastatin 80 mg and placebo in standardised neuropsychological tests.
News • 22-3-2017
New heart failure agent also reduces HbA1c levels
In addition to its cardiovascular benefits, the ARNI sacubitril/valsartan also reduces HbA1c levels, compared to enalapril.
News • 21-3-2017
No role for aspirin in long-term prevention of recurrent VTE
In the EINSTEIN CHOICE study, rivaroxaban, at both 20 mg and 10 mg doses, was more effective than aspirin for the prevention of recurrent venous thromboembolism after 6 to 12 months of therapy.
Physical activity and BMI show dose-response association with risk of heart failure
13-3-2017 • Pandey A J Am Coll Cardiol. 2017
In a pooled analysis of individual-level data from 3 prospective studies, a dose–response association between physical activity, BMI, and risk of HF was observed, particularly in HFpEF patients.
Preterm delivery associated to maternal CVD risk
1-3-2017 • Tanz LJ, et al, Circulation, 2017
Preterm delivery is independently predictive of CVD which is only partially explained by postpartum development of traditional CVD risk factors.
57% decrease in ischaemic stroke incidence by changing risk factors
21-2-2017 • Vangen-Lønne AM, et al, Stroke, 2017
In an analysis from data between 1995 to 2012, changes in risk factors accounted for 57% of the decreased IS incidence and most important contributors were decline in SBP and prevalence of smoking.
All upcoming meetings...
Meeting reports & resources
EPCCS Guidance Documents
Evidence- and meeting-based guidance for primary care
Report of 8th Annual EPCCS meeting held in Prague.
Report of 7th Annual EPCCS meeting held in Brussels.
Report of 6th Annual EPCCS meeting held in London
All meeting reports...